What's the price of txmd stock?
Since then, TXMD stock has decreased by 62.6% and is now trading at $0.5690. View which stocks have been most impacted by COVID-19. When is TherapeuticsMD's next earnings date?
Who buys Dynex capital (DXDX) stock?
DX stock was bought by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL. Company insiders that have bought Dynex Capital stock in the last two years include Byron L Boston, David H Stevens, Smriti Laxman Popenoe and Stephen J Benedetti.
Where can I buy DX shares?
Shares of DX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is DX capital a great dividend paying stock?
Dynex Capital pays an annual dividend of $1.56 per share and currently has a dividend yield of 9.32%. DX has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
See more
What is going on with Therapeutics MD?
(RTTNews) - Women's healthcare company TherapeuticsMD, Inc. (TXMD), on Tuesday announced that it has entered into a definitive merger agreement, to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in healthcare companies.
Who bought TherapeuticsMD?
EW Healthcare PartnersTherapeuticsMD will be acquired by private equity firm EW Healthcare Partners in a deal valued at $177 million.
Is TherapeuticsMD stock a buy?
Is TherapeuticsMD Inc stock A Buy? The TherapeuticsMD stock holds several negative signals and despite the positive trend, we believe TherapeuticsMD will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Will TXMD stock go up?
Stock Price Forecast The 2 analysts offering 12-month price forecasts for TherapeuticsMD Inc have a median target of 5.50, with a high estimate of 10.00 and a low estimate of 1.00. The median estimate represents a -15.77% decrease from the last price of 6.53.
Should I sell my TXMD stock?
The consensus among Wall Street analysts is that investors should "hold" TherapeuticsMD stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
Did TXMD do a reverse split?
The Company expects that the effective time of the Reverse Stock Split will be on or about 5:00 pm New York time on Friday, May 6, 2022, with the Common Stock trading on a post-split basis under the Company's existing trading symbol, “TXMD,” at the market open on Monday, May 9, 2022.
Can TXMD delist?
The Company has notified the NYSE American that it will voluntarily delist its common stock from the NYSE American. The last day of trading of the Company's common stock on the NYSE American is expected to be on October 8, 2017 .
Is TXMD being shorted?
Short Shares Availability This table shows the number of shares of US:TXMD available to be shorted at a leading prime brokerage.
What does a 1 for 4 reverse stock split mean?
In a 1-for-4 split, a shareholder of four shares will end up with one share. The price of one share will be the sum of all the four shares, enhancing the per-share value. The market capitalization value remains the same as there are no new additions, only a restructuring.
Is CEI a good investment?
CEI has an overall F rating, which equates to a Strong Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree. CEI has an F grade for Value, Stability, and Quality.
What does a 1 for 4 reverse stock split mean?
In a 1-for-4 split, a shareholder of four shares will end up with one share. The price of one share will be the sum of all the four shares, enhancing the per-share value. The market capitalization value remains the same as there are no new additions, only a restructuring.
What is a reverse split in stock market?
A reverse stock split occurs when a publicly traded company divides the number of outstanding shares by a certain amount. This serves to decrease the number of outstanding shares and increase the price per share of those outstanding shares.
Should I buy or sell TherapeuticsMD stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last twelve months. There are curr...
What is TherapeuticsMD's stock price forecast for 2022?
3 equities research analysts have issued 12-month price targets for TherapeuticsMD's shares. Their forecasts range from $125.00 to $250.00. On aver...
How has TherapeuticsMD's stock performed in 2022?
TherapeuticsMD's stock was trading at $17.7750 at the beginning of the year. Since then, TXMD shares have decreased by 44.0% and is now trading at...
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest in May. As of May 31st, there was short interest totaling 2,010,000 shares, an increase of 36.7% fr...
When is TherapeuticsMD's next earnings date?
TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Ther...
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its earnings results on Monday, May, 16th. The company reported ($5.69) earnings per share (EPS) for t...
When did TherapeuticsMD's stock split? How did TherapeuticsMD's stock split work?
TherapeuticsMD's stock reverse split on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares ow...
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the following people: Mr. Robert G. Finizio , Co-Founder (Age 51, Pay $1.22M) ( LinkedIn Profile ) Dr....
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Esperion Therapeutics (ESPR) , OrganiGram (OGI) , Radius Health (RDUS) , Generation B...
About TherapeuticsMD
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
When will TXMD report results?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TherapeuticsMD stock. View analyst ratings for TherapeuticsMD or view top-rated stocks.
When is TherapeuticsMD's earnings call 2021?
(NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets.
Problems with Current Medical Enterprise Software
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / TherapeuticsMD, Inc. (NASDAQ:TXMD) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 8:30 AM Eastern Time.
DXMD Token Uses
While health care data belongs to patients, the data is currently extremely centralized and in the hands of corporations. For example, Epic Systems Corporation and Cerner Corporation control 50% of the patient data in the acute care market.
Our Roadmap
DXMD is designed to be a utility token only. The core of the DXMD Token is functionality on the DXMD Network. Below are some examples of DXMD Token's utility in the future.
Join The Decentralized Medicine Movement
Below is a roadmap of what we are working towards and hope to work on in the future. It is worth noting that blockchain industry and blockchain regulations are still very new and rapidly changing so our roadmaps is in no way a guarantee of products, just a roadmap of what we hope to work towards.
How many shares of Dynex Capital are there after the split?
We are rapidly expanding our team and looking for individuals who are passionate about blockchain technology and medicine to join our team. Please contact us below if you're interested.
Why is Dynex Capital's payout ratio above 75% not desirable?
An investor that had 100 shares of Dynex Capital stock prior to the reverse split would have 33 shares after the split.
Is Dynex a good dividend stock?
Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, Dynex Capital will have a dividend payout ratio of 81.68% in the coming year. This indicates that Dynex Capital may not be able to sustain their current dividend. View Dynex Capital's dividend history.
